(RTTNews) - Royalty Pharma plc (RPRX), the largest buyer of biopharmaceutical royalties and a major funder of life sciences innovation, reported higher third-quarter 2026 portfolio receipts and raised its full-year outlook.

Royalty Pharma Q3 Results Show Growth; Raises FY26 Receipts Outlook To $3.55 Bln 

Key PointsRoyalty Pharma shares have surged ahead of the biotech funding company's Nov. 4 quarterly earnings release.

Should You Buy Royalty Pharma Stock Before Nov. 4?

Key PointsRoyalty Pharma is not a drug maker.

Forget Biotech's Binary Bets: This Dividend Stock Collects Royalties on Blockbusters Instead

Key PointsRoyalty Pharma offers exposure to a diversified portfolio of promising drug products and candidates.

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Royalty Pharma plc News